Melinta Therapeutics

Melinta Therapeutics, founded in 2000 as Rib-X Pharmaceuticals, is an American publicly traded biopharmaceutical firm that focuses on the design and development of novel broad-spectrum antibiotics for the treatment of antibiotic-resistant infections in hospital and community settings. The company is located in New Haven, Connecticut.[1]

Melinta Therapeutics
IndustryPharmaceutical
Founded2000
HeadquartersMorristown, NJ
Area served
Worldwide
ProductsBroad-spectrum antibiotics
Websitehttp://melinta.com/

In mid-2011, Sanofi entered into a global research collaboration and licensing option with the company to develop and commercialize novel antibiotics.[2] It was renamed Melinta Therapeutics in 2013.[3]

One of its products, delafloxacin (Baxdela), a fluoroquinolone antibiotic acquired from Wakunaga Pharmaceutical in 2006,[2] was approved by the FDA in 2017.[4]

As of 2016, the company was also developing radezolid, a next-generation oxazolidinone for bacterial acne.[3]

Melinta moved its headquarters to Morristown, New Jersey in early 2019.

On December 27, 2019, Melinta Therapeutics filed for Chapter 11 bankruptcy protection.[5]

References
  1. Carroll, John (2011). "Rib-X Pharmaceuticals - 2011 Fierce 15". FierceBiotech.
  2. Cartwright, Heather (12 July 2011). "Rib-X Pharmaceuticals Signs Global Antibiotic Research Collaboration with Sanofi". PharmaDeals Review (7). doi:10.3833/pdr.v2011i7.1494. Archived from the original on 25 April 2012.
  3. Stearns, John (August 1, 2016). "Melinta Therapeutics takes aim at deadly drug-resistant bacteria". Hartford Business Journal.
  4. Osborne, Randy (20 June 2017). "Melinta's I.V., oral delafloxacin wins FDA nod in skin infections". BioWorld.
  5. "Antibiotics maker Melinta files for Chapter 11 bankruptcy". Reuters. 2019-12-27. Retrieved 2019-12-29.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.